









Markets
/
Stocks
/
nasdaq-abeo
/

Abeona Therapeutics Inc

ABEO

4.135USD

-0.055-1.31%

Market hours （ET）Quotes delayed by 15 min

211.91MMarket Cap

3.70P/E TTM



Abeona Therapeutics Inc

4.135

-0.055-1.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Abeona Therapeutics Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Abeona Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

52 / 159

Overall Ranking

153 / 4615

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

20.500

Target Price

+370.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Abeona Therapeutics Inc Highlights

StrengthsRisks

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is 3.96, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 37.80M shares, increasing 1.59% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 687.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.04.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.23, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.23

Change



Financials

9.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Abeona Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.23, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 3.96, which is 72.55% below the recent high of 6.84 and 451.87% above the recent low of -13.94.

Score

Industry at a Glance

Previous score

7.23

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 52/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 9.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Abeona Therapeutics Inc is 20.00, with a high of 27.50 and a low of 14.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

20.500

Target Price

+370.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Abeona Therapeutics Inc

ABEO

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.58, which is lower than the Pharmaceuticals industry's average of 6.90. Sideways: Currently, the stock price is trading between the resistance level at 5.23 and the support level at 3.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.195

Sell

RSI(14)

22.290

Sell

STOCH(KDJ)(9,3,3)

5.903

Oversold

ATR(14)

0.257

Low Volatility

CCI(14)

-158.861

Sell

Williams %R

94.020

Oversold

TRIX(12,20)

-0.635

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.540

Sell

MA10

4.907

Sell

MA20

5.168

Sell

MA50

5.634

Sell

MA100

5.999

Sell

MA200

5.770

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 73.72%, representing a quarter-over-quarter increase of 2.72%. The largest institutional shareholder is The Vanguard, holding a total of 2.60M shares, representing 5.08% of shares outstanding, with 17.85% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nantahala Capital Management, LLC

4.56M

+4.46%

Adage Capital Management, L.P.

3.07M

+14.17%

BlackRock Institutional Trust Company, N.A.

2.72M

+475.57%

Suvretta Capital Management, LLC

2.68M

-27.39%

The Vanguard Group, Inc.

Star Investors

2.51M

+24.10%

Western Standard, LLC

2.09M

-8.31%

Vivo Capital, LLC

1.84M

Boone Capital Management LLC

1.25M

Seshadri (Vishwas)

1.19M

-3.59%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 5.63, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.